[Skip to Content]
[Skip to Content Landing]
Views 4,996
Citations 0
Editorial
September 3, 2019

Breast Cancer Chemoprevention—Can We Make a Case for Precision Medicine?

Author Affiliations
  • 1Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
  • 2Population Studies Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania
JAMA Oncol. Published online September 3, 2019. doi:10.1001/jamaoncol.2019.3785

Among women in the United States, breast cancer remains the most common cancer and is the second leading cause of cancer-related deaths. The median age at diagnosis for white women is 63 years and is younger for black women at 59 years. In addition to earlier age at diagnosis, breast cancer tends to be more aggressive in black women, and they are more likely to die of complications of the disease at every age. While incidence rates have remained relatively stable, mortality rates have significantly declined over the past 30 years. This decline is thought to be related to earlier detection by widespread screening and improved therapies.1

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×